the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Share this:
Brief Title Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
Official Title A Feasibility Study of Sequential Hepatic Internal Radiation and Systemic Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastatic to Liver.
Principal Investigator Luke, Jason
Brief Summary Reports to date show limited efficacy of immunotherapy for uveal melanoma. Recent experimental and clinical evidence suggests synergy between radiation therapy and immunotherapy. The investigators will explore this synergy with a feasibility study of 18 patients with uveal melanoma and hepatic metastases who will receive SirSpheres Yttrium-90 selective internal hepatic radiation followed by immunotherapy with the combination of ipilimumab and nivolumab.
Gender All
Ages 18 Years
Enrollment 18
Accepts Healthy Volunteers No
Lead Sponsor David Minor, MDOther
Collaborator California Pacific Medical CenterOther
Study Design
Study Phase Phase 1/Phase 2
Study Type Interventional
Contact Name Kevin B Kim, MD
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Uveal Melanoma
Detail for Health Professional (on clinicaltrials.gov)
More clinical trials by this PI